SIMULTANEOUS DETERMINATION OF LEVAMISOLE AND OXYCLOZANIDE IN THE PHARMACEUTICAL PREPARATION BY GC-MS

Mohamed W. I. Nassar¹, Ahmed El-Olemy¹, Mohamed S. Emara¹, and Ahmed M. Ahmed^{*2}

¹Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, 11751, Cairo, Egypt.

²Higher Committee of Medical Specialists Ministry of Health and Population, Giza, Egypt.

* Corresponding author: E-mail: <u>ahmedabdrabou31@yahoo.com</u>

ABSTRACT

A sensitive, precise, and accurate gas chromatography-mass spectrometry method was developed for the simultaneous determination of levamisole and oxyclozanide in pure samples and pharmaceutical preparation. Gas chromatography was presented as a simple separation analytical method for the simultaneous analysis of the deliberated drugs within a shorter analytical run time. In this study, separation was achieved using a ZB5 column with (30 m ×0.53 mm, 1.50 µm), and helium as a carrier gas. The proposed method showed well separation between the drugs and each other and had good accuracy. The method showed to be linear ($r^2 = 0.9998$), precise (RSD < 0.496%), accurate (recovery of 99.37% for levamisole and 100.14% for oxyclozanide), specific and robust. LOD and LOQ values were 0.935 ng mL⁻¹ and 3.085 ng mL⁻¹ respectively for levamisole and 0.884 ng mL⁻¹ and 2.917 ng mL⁻¹ respectively for oxyclozanide. The proposed method obtained well separation and had perfect accuracy. The method was validated according to ICH guidelines and carried out to determine the cited drugs in their pharmaceutical preparation.

Keywords: Levamisole, Oxyclozanide, Gas chromatography, Pharmaceutical preparation.

INTRODUCTION

Levamisole,(6S)-6-Phenyl-2,3,5,6-terahydroimidazo[2,1-b]thiazole, is an active levo-isomer of tetramisole, that is used in combination with oxyclozanide for the treatment of worm infestations (The British Pharmacopoeia 2011, Martindale 2009). Levamisole is soluble in methanol, and practically insoluble in water. It has a molecular formula of $C_{11}H_{12}N_2S$, and molecular weight of 204.29 g/mol as shown in **Fig 1(a)** (The British Pharmacopoeia 2011). Levamisole is official in European Pharmacopoeia (The European Pharmacopoeia 2008), British Pharmacopoeia (The British Pharmacopoeia 2011), oxyclozanide, 3,3',5,5',6-pentachloro-2' hydroxy - salicylanilide, is an anthelmintic drug (The British Pharmacopoeia 2011). Oxyclozanide is freely soluble in acetone, methanol and ethanol, and practically insoluble in water. It has a molecular formula of C₁₃H₆Cl₅NO₃, and molecular weight of 401.45 g/mol as shown in **Fig 1(b)** (The British Pharmacopoeia 2011). Oxyclozanide is official in British Pharmacopoeia (The British Pharmacopoeia 2011). Levamisole and oxyclozanide combination therapy is formulated as an oral suspension, and indicated for the treatment of worm infestations in animals (Mohamed et al. 2014). Levozan[®] is a medication used to treat worm infestations in animals. It is approved for treatment and control of parasitic gastroenteritis, verminous bronchitis, and liver flukes infestation. There are different analytical techniques applied for the determination of levamisole in pharmaceutical formulation and in biological fluid such as titrimetric (Cao et al. 1992, Xu et al. 1997), spectrophotometric (Syed et al. 2020), HPLC (Tong et al. 2011, Cherlet et al. 2000), and GC methods (Trehy et al. 2011). There are different analytical techniques applied for the determination of oxyclozanide in pharmaceutical preparation and in biological fluid such as titrimetric (The British Pharmacopoeia 2011), spectrophotometric (Mohamed et al. 2014, Dinc et al. 2002), HPLC (Khan et al. 2000), and GC methods (Bluethgen et al. 1982) and there are another available instrumental techniques for the determination of levamisole and oxyclozanide as a combination in the pharmaceutical preparation, the available techniques include a spectrophotometric method, TLC, and HPLC methods (Whelan et al. 2010). The aim of the present work was to develop a validate new method for the determination of levamisole and oxyclozanide in pure form and its pharmaceutical preparation. The developed method was validated in accordance with ICH guidelines Q2 (R1) (ICH Q2 (R1) 2005).




Figure 1: structural formula of (a) levamisole and (b) oxyclozanide.

1. EXPERIMENTAL

2.1. Pure sample

Pure levamisole (Its purity was found to be $99.48\pm1.061\%$ according to the official method (BP, 2011)) and oxyclozanide (Its purity was found to be $99.69\pm0.976\%$ according to the manufacturer's method) were obtained from Brihan Laboratories Pvt Ltd Bhosari, Pune, and kindly supplied by Egyptian International Center for Import (Cairo, Egypt).

2.2. Pharmaceutical preparation

Levozan[®] oral suspension (Power Vet Company, Batch number. V100503, and expire date April- 2023) imported by International Center for Import (Cairo, Egypt). Each 1ml is claimed to contain 30 mg of Levamisole and 60 mg of oxyclozanide.

2.3. Chemicals and reagents

Methanol, HPLC grade (Sigma-Aldrich, Steinheim, Germany).

Double deionized Water.

Helium gas.

Phosphate buffer (25Mm, pH 7) prepared using monosodium phosphate and disodium phosphate as prescribed in USA pharmacopeia (Sigma-Aldrich, Steinheim, Germany).

Acetonitrile, HPLC grade (Sigma-Aldrich, Steinheim, Germany).

Ortho-phosphoric acid (Sigma-Aldrich, Steinheim, Germany).

N,O-Bis(trimethylsilyl)acetamide (BSA), for GC derivatization, LiChropurTM, \geq 98.5% (GC) (Sigma-Aldrich, Steinheim, Germany) (made by the reaction of acetamide with a large excess of Chlorotrimethylsilane in the presence of Triethylamine).

Sodium decanesulfonate (30 mM) and triethyl amine were purchased from Pectrochem Pvt. Ltd., Mumbai.

2.4. Apparatus

The GC Perkin Elmer Clarus 500 model (Perkin Elmer Technologies, USA), Mass detector (Perkin Elmer Technologies, USA). The control of the GC system and data processing were performed using PerkinElmer TurboMass[™] GC/MS software.

2.5. Standard solutions

Standard stock solution (200 μ g mL⁻¹) of each levamisole and oxyclozanide were prepared separately in methanol. Preparation of working solutions of levamisole and oxyclozanide in the required concentration range was adjusted by dilution of standard stock solutions with the same solvent and derivatization was performed using BSA. The stock solutions were prepared once a month, kept at 2–8 °C in a refrigerator and brought to room temperature before use.

2.6. Procedure

2.6.1. Chromatographic condition

A Zebron ZB5 column (30m, 0.53 mm, 1.50 μ m, Phenomenex, USA) was used for the chromatographic separation. Helium was applied as a carrier gas, with a flow rate of 1.5 mL min⁻¹ and an injection volume of 2 μ L. The oven temperature program was as follows: initial temperature maintained at 70 °C for 1 min, raised to 270 °C at a rate of 20 °C /min, hold 4 min, then raised to 300 °C at a rate of 10 °C/min, hold 3 min, and the injector temperature was maintained at 280 °C. Methanol was used as a diluent. The mass spectrometry ionization modes were electron ionization (standard) positive/negative chemical ionization (optional); compounds leaving the GC column are fragmented by electron impact. Selected ion monitoring (SIM) was used as an acquisition mode in order to increase the detector sensitivity of the measurement. The charged fragments are detected, and the subsequent spectrum obtained can be used for identifying the molecule. Fragmentation patterns are reproducible and can be used to produce quantitative measurements.

2.6.2. Construction of the calibration graph

Six different concentrations of standard solutions $(4-120 \text{ ng mL}^{-1})$ of both levamisole and oxyclozanide were injected separately injected into GC-MS system. The procedure was performed in triplicate for each concentration. The analyte response (Peak Area) obtained was plotted against the corresponding concentration of the analyte (expressed as ng mL⁻¹).




Figure 2. GC chromatogram of levamisole (A) (60 ng mL⁻¹) and oxyclozanide (B) (60 ng mL⁻¹).

Derivatization

Derivatization of standards and sample solutions were prepared from the dry residues (where the standard and samples solutions were diluted to obtain a solution containing 12 ng mL⁻¹ of levamisole and 24 ng mL⁻¹ of oxyclozanide, and then 250 μ L of the solution in microvial was evaporated to dryness using nitrogen) by reacting with 50 μ L BSA solution at 80 °C for 15 min in an airtight glass vial; the obtained solutions were cooled before being injected into GC.

2.6.3. Application to pharmaceutical preparation

Two mL of Levozan[®] oral suspension equivalent to 60 mg of levamisole and 120 mg of oxyclozanide, were quantitatively transferred to a 100 mL volumetric flask, and the volume was made up to 50 mL with methanol. The solution was shaken vigorously for 20 min and filtrated. The volume was completed with diluent to produce a stock solution labeled to contain 0.6 mg mL⁻¹ levamisole and 1.2 mg mL⁻¹ of oxyclozanide. This

stock solution was diluted to obtain a test sample solution containing 12 ng mL⁻¹ of levamisole and 24 ng mL⁻¹ of oxyclozanide, and then 250 μ L of the test sample solution in microvial was evaporated to dryness using nitrogen followed by derivatization using BSA and then injected into GC-MS system.

2. RESULTS AND DISCUSSION

3.1. Method development

Optimization of mass spectrometry parameters and chromatographic conditions was achieved to develop and validate a selective and rapid assay method for the determination of levamisole and oxyclozanide.

The determination of levamisole and oxyclozanide was successful by applying the GC-MS method in pure samples and pharmaceutical preparations without any interference in the results or between the compounds and each other. Several mobile phases were used to identify the mentioned compounds as a mixture and the best choice was methanol. No obstacles were observed during the analysis, and it was great.

This method contributes to the determination of levamisole and oxyclozanide using a developed, accurate and rapid method, and all the results of the analyzes were within the permissible limits.

Optimization of experimental conditions

The chromatographic separation was optimized after taking into account the resolution between the drugs and their degradation product. Helium was applied as a carrier gas. The column was performed by a flow rate of 1.5 mL min⁻¹ and an injection volume of 2 μ L. Methanol was the best choice to separate the intact drugs from their degradation product. The chromatogram of the standard solution of levamisole and oxyclozanide was shown in Fig. 2.

3.2. Method validation

3.2.1. Linearity and range

A linearity relationship was established by plotting the peak area values of the analyte versus the corresponding concentrations in ng mL⁻¹. The regression data results were summarized in **Table 1**.

3.2.2. Limit of detection and limit of quantification

LOD and LOQ were calculated according to ICH by comparing measured signals from samples with known low concentrations of the analyte with those of blank samples and establishing the minimum concentration at which the analyte can be reliably detected. The analytical parameters of the proposed methods are summarized in **Table 1**

3.2.3. Accuracy and precision.

Accuracy and precision were evaluated at three different concentration levels within the same day to obtain repeatability (intra-day precision) and over three different days to obtain intermediate precision (inter-day precision). The accuracy and precision were calculated and expressed in terms of percent recovery and standard deviation, respectively. All values were within the acceptance variability limits as shown in **Table1**.

3.2.4. Specificity

The specificity of the method was confirmed by determination of different laboratory prepared mixtures of levamisole and oxyclozanide in different ratios. The provided chromatograms revealed that levamisole and oxyclozanide were clearly completely separated from each other confirming the specificity and selectivity of the proposed method. Also the specificity was evaluated by observing possible interference from suspension excipients. This was achieved by the analysis of suspension where the recorded chromatograms did not show any additional peaks when compared to those of the synthetic mixture.

Table 1: Regression and validation data for estimation of levamisole and oxyclozanide by the proposed method.

Parameter	Levamisole	Oxyclozanide
Linearity range (ng mL ⁻¹)	4-120	4-120
LOD (ng mL ⁻¹)	0.935	0.884
LOQ (ng mL ⁻¹)	3.085	2.917
Regression parameter*	Y = a + b C	Y = a + b C
Correlation coefficient	0.9998	0.9998
Slope (b)	54189	3986.7
Intercept (a)	-29084	-1500.9
Precision (% RSD)		
Repeatability	0.288	0.296
Intermediate precision	0.374	0.383
Robustness (%RSD)		
Flow Rate (±0.1mL)	0.478	0.496
GC oven temperature (±1 ^C C)	0.347	0.384

*Y= a + bC, where Y is the peak area and C is the concentration in ng mL⁻¹.

	Pharmaceutical	Pure added	Pure found	%Recovery
Drug	taken (ng mL ⁻¹)	(ng mL ⁻¹)	(ng mL ⁻¹)	5
		16	15.87	99.21
Levamisole	20	20	19.92	99.58
		24	23.83	99.32
	Mean \pm %)	99.37 ± 0.845
		16	16.04	100.24
Oxyclozanide	20	20	19.94	99.72
		24	24.11	100.46
		Mean ± % RS	D	$\begin{array}{c} 100.14 \pm \\ 0.646 \end{array}$

 Table 2: Recovery study of levamisole and oxyclozanide by applying standard addition technique:

3.2.5. System suitability

System suitability test was applied to verify that an analytical method was suitable for its intended purpose; the items measured were resolution, tailing factor, and theoretical plate and all results were observed within the acceptance range, as shown in **Table 3**.

Table 3: System	suitability test	for levamisole and	oxyclozanide

	Results		
Criteria	Levamisole	Oxyclozanide	
The %RSD for five replication injections of standard preparation for levamisole and oxyclozanide	0.294	0.314	
Resolution	1.26	1.26	
The Tailing factor	1.56	1.43	
Theoretical Plates	2675	2968	

3.2.6. Robustness

Robustness was evaluated by changing the flow rate $(1.5 \pm 0.1 \text{ml min}^{-1})$. The effect of GC oven temperature was studied on pure samples of the selection drugs at $70 \pm 1^{\circ}$ C (optimized temperature was 70°C). The measured response variances were the % RSDs as shown in **Table 1**. The degree of reproducibility of the results obtained as a result of small deliberate variations in the method parameters has proven that the method is robust.

3.2.7. Application to the finished product

The proposed method was applied successfully for determination of levamisole and oxyclozanide in levozan[®] oral suspension. The obtained results showed absence of any interference from either excipients or additives. The results of the proposed method were compared with that of the reported method (Kemal. et al. 2020). The proposed method showed good accuracy and precision for assay of levamisole and oxyclozanide in Levozan[®] oral suspension and the values were listed in **Table 4**.

Parameter	Proposed method		Reported method *	
	Levamisole	Oxyclozanide	Levamisole	Oxyclozanid e
n ^a	5	5	5	5
% R	99.37	100.14	100.37	100.45
%RSD	0.845	0.646	0.848	0.800
SD	0.840	0.647	0.851	0.803
Variance	0.705	0.418	0.724	0.645
Student's t-test				
	1.877	0.658		
(2.306) ^b				
F-value	0.974	0.648		
(6.388) ^b				

Table 4: Results obtained after determination of levamisole and oxyclozanide in Levozan oral suspension and comparison with the reported method.

^aExperiments number.

^bTabulated values of "t "and "F" at (P = 0.05).

*Reported method: HPLC method using C18 column, mobile phase consisting of acetonitrile: methanol: 25mM phosphate buffer at pH 7.0 containing 30 mM sodium decanesulfonate and triethylamine (50:50:1 by volume) with pH adjusted to 7.0 using ortho-phosphoric acid [51:49 by volume], and using UV detector at, 220 nm (Kemal. et al. 2020).

The proposed work shows better sensitivity than the reported method, as when using highly sensitive automated systems such as GC-MS we can get better and more accurate results (linear range, accuracy, precision, recovery, sample volume and sample preparation time) besides that it shortens time and effort.

3. CONCLUSION

This method is sensitive, selective and rapid, which can be applied for determination of levamisole and oxyclozanide in their pharmaceutical preparation by GC –MS. These methods have wider range with good accuracy and precision. They can be used for the routine analysis of both drugs in pharmaceutical preparation.

REFERENCES

- Bluethgen A. et al, (1982), Milchwissenschaft, Through Analytical Abstract C.D. Gas chromatographic. determination of fasciolacide residues in milk, 37(4), 206-21.
- **Cao G. et al, (1992)**, Assay of ethambutol hydrochloride, mecillinam and levamisole hydrochloride tablets by linear titration, 27(2), 96-98.
- **Cherlet M. et al, (2000),** Quantitative analysis of levamisole in porcine tissues by highperformance liquid chromatography combined with atmospheric pressure chemical ionization mass spectrometry, Chromatogr J.,-B:-Biomed. Appl, 742(2), 283-293.
- **Dinc E. et al, (2002)**, Spectrophotometric multicomponent resolution of a veterinary formulation containing oxfendazole and oxyclozanide by multivariate calibration-prediction techniques, J. Pharm. Biomed. Anal, 28(3-4), 779-788.
- **International conference on Harmonization, ICH Q2 (R1)**: Validation of analytical procedures: text and methodology (2005).
- Khan A. R. et al, (2000), LC assay method for oxfendazole and oxyclozanide in pharmaceutical preparations, J. Pharm. Biomed. Anal, 22(1), 111-114.
- Kemal H.S. et al, (2020), Development and Validation of RP-HPLC Method for the Simultaneous Determination of Levamisole HCl and Oxyclozanide and its Application in the Assay of Veterinary Bolus Formulations, Current Pharmaceutical Analysis, 17(5), 679-689.

Martindale "The Complete DrugReference, 2009.

- Mohamed A. O. et al, (2014), Simultaneous determination of oxyclozanide and levamisole by spectrophotometric and chromatographic methods, Journal of Applied Pharmaceutical Science, 4(9):36-45.
- **Syed S. M. et al, (2020)**, A Validated UV Spectroscopic Method for determination of Levamisole HCl, International Journal of Pharmaceutical Research and Applications, 5(1): 97-101.
- The British Pharmacopoeia (Veterinary), Her Majesty's Stationary Office, London, UK, 2011, 91, 78.
- The European Pharmacopoeia, 7th ed., Council of Europe, Strasbourg, 2008, 2350.
- The United States pharmacopeia 34, NF 29, Asian Ed. Rand Mc Nally, USA, 2011, 245, 3284.
- Tong L. et al, (2011), Analyt, Technol. Biomed. Life. Sci, A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to

pharmacokinetic study. Manufacturer, s procedure, Middle Eastm Cairo. Egypt, 879(5-6), 299-303.

- **Trehy M. L. et al, (2011)**, Determination of Levamisole in Urine by Gas Chromatography-Mass Spectrometry, Journal of Analytical Toxicology, 35(8):545-50.
- Whelan M. et al, (2010), Investigation of the persistence of levamisole and oxyclozanide in milk and fate in cheese, J Agric Food Chem, 58(23):12204-9.
- Xu G. et al, (1997), Through Analytical Abstract C.D. Fixed-pH titration method for weakly acidic and basic drugs 16(5), 17-20.

التحديد المتزامن لمادة الليفاميزول والأوكسيكلوزانيد في المستحضر الصيدلاني باستخدام

كروماتوجرافيا الغاز - قياس الطيف الكتلي

محمد وفاء نصار ¹ وأحمد العليمي¹ ومحمد عمارة¹ وأحمد محمد أحمد *²

1 قسم الكيمياء التحليلية الصيدلانية ، كلية الصيدلة ، جامعة الأزهر ، 11751 ، القاهرة ، مصر.

2 اللجنة العليا للتخصصات الطبية ، وزارة الصحة والسكان ، الجيزة ، مصر.

البريد الالكتروني للباحث الرئيسي : ahmedabdrabou31@yahoo.com

تم تطوير طريقة قياس الطيف الكتلي الحساسة والدقيقة للغاز من أجل التحديد المتزامن للليفاميزول والأوكسيكلوزانيد في العينة النقية والمستحضرات الصيدلانية. تم تقديم كروماتو غرافيا الغاز كطريقة تحليلية بسيطة والأوكسيكلوزانيد في العينة النقية والمستحضرات الصيدلانية. تم تقديم كروماتو غرافيا الغاز كطريقة تحليلية بسيطة الفصل من أجل التحليل المتزامن للعقاقير المدروسة خلال وقت تشغيل تحليلي أقصر. في هذه الدراسة ، تم تحقيق الفصل من أجل التحليل المتزامن للعقاقير المدروسة خلال وقت تشغيل تحليلي أقصر. في هذه الدراسة ، تم تحقيق الفصل من أجل التحليل المتزامن للعقاقير المدروسة خلال وقت تشغيل تحليلي أقصر. في هذه الدراسة ، تم تحقيق الفصل باستخدام عمود 205 (30 م × 0.53 مم ، 150 ميكرومتر) ، والهليوم كغاز حامل. أظهرت الطريقة الفصل باستخدام عمود 700 م × 0.53 مم ، 100 ميكرومتر) ، والهليوم كغاز حامل. أظهرت الطريقة المقترحة فصل جيد بين الأدوية بعضها البعض بدقة جيدة. أظهرت الطريقة أنها خطية (20998) و وقيقة (2000 م × 0.53 ميكرومتر) ، والهليوم كغاز حامل. أظهرت الطريقة المقترحة فصل جيد بين الأدوية بعضها البعض بدقة جيدة. أظهرت الطريقة أنها خطية (20998) و 2000 مع المقترحة فصل جيد بين الأدوية بعضها البعض بدقة حيدة. أظهرت الطريقة أنها خطية (2000 م حكورة 2000) و 2000 مع مع المقترحة ومال إلى ومحدة وقوية. كانت قيم لما لمول للدولي للكوكسيكلوزانيد) و 2000 معددة وقوية. كانت قيم و 2001 و 2001 ملولي للليفاميزول و 2000 ما مل مل مل و 2005 للوغرام / مل مل و 2005 مع مات على فصل جيد ودقة تامة. تم و 2015 نانو غرام / مل على التوالي للليفاميزول و 2005 نانو غرام / مل ملوز و 2005 نانو غرام / ملوو و 2005 نانو خار و 2005 نانو خاو و 2005 نانو 2005 نانو 3

الكلمات المفتاحية : ليفاميزول ، أوكسيكلوزانيد ، كروماتوغرافيا الغاز - قياس الطيف الكتلي، المستحضرات الصيدلانية.